{"id":1028,"date":"2026-02-02T13:51:29","date_gmt":"2026-02-02T13:51:29","guid":{"rendered":"http:\/\/littleheroesfoundation.org\/?p=1028"},"modified":"2026-02-02T13:51:29","modified_gmt":"2026-02-02T13:51:29","slug":"moreover-the-candidate-still-induces-immunity-against-the-measles-recognized-as-a-looming-second-menace-when-countries-are-forced-to-stop-routine-vaccination-campaigns-in-the-face-of-covid","status":"publish","type":"post","link":"https:\/\/littleheroesfoundation.org\/?p=1028","title":{"rendered":"\ufeffMoreover, the candidate still induces immunity against the measles, recognized as a looming second menace, when countries are forced to stop routine vaccination campaigns in the face of COVID-19"},"content":{"rendered":"

\ufeffMoreover, the candidate still induces immunity against the measles, recognized as a looming second menace, when countries are forced to stop routine vaccination campaigns in the face of COVID-19. Abstract == The COVID-19 pandemic is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and has spread worldwide, with millions of cases and more than 1 million deaths to date. The gravity of the situation mandates accelerated efforts to identify safe and effective vaccines. Here, we generated measles virus (MeV)-based vaccine candidates expressing the Valnoctamide SARS-CoV-2 spike glycoprotein (S). Insertion of the full-length S protein gene in two different MeV genomic positions resulted in modulated S protein expression. The variant with lower S protein expression levels was genetically stable and induced high levels of effective Th1-biased antibody and T cell responses in mice after two immunizations. In addition to neutralizing IgG antibody responses in a protective range, multifunctional CD8+and CD4+T cell responses with S protein-specific killing activity were detected. Upon challenge using a mouse-adapted SARS-CoV-2, virus loads in vaccinated mice were significantly lower, while vaccinated Syrian hamsters revealed protection in a harsh challenge setup using an early-passage human patient isolate. These results are highly encouraging and support further development of MeV-based COVID-19 vaccines. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) belongs toCoronaviridaefamily and emerged toward the end of 2019 as causative agent of pneumonia in the Hubei province in China (1). The World Health Organization named the disease Corona Virus Disease-2019 (COVID-19), and officially declared the pandemic state on March 11, 2020. Human coronaviruses have been known for decades as one of the causative agents of the common cold, but two previous coronavirus outbreaks, caused by the severe acute respiratory syndrome virus (SARS-CoV-1) and the Middle East respiratory syndrome virus (MERS-CoV), have demonstrated the remarkable pathogenic potential of human beta coronaviruses. Around 10,000 people have been infected by SARS and MERS, which has resulted in a death toll of about 1,500 patients, but the outbreaks remained largely confined in terms of time or spread, respectively. In contrast, SARS-CoV-2 spreads Rabbit Polyclonal to UGDH<\/a> effectively and at a rapid pace by direct transmission, with a reproductive number R0of at least 2 to 2.5 (2,3). Due to high transmissibility and extensive community spread, Valnoctamide this novel coronavirus has already caused over 36.2 million infections and over 1 million deaths (as of October 9, 2020;https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019), while worldwide shutdowns of social Valnoctamide<\/a> life and economy to confine the spread of this respiratory virus have considerable impacts. After the emergence of SARS in 2002 and then MERS in 2012, vaccine development efforts have been initiated, including the use of recombinant measles virus (MeV) vaccine as a platform concept (4), to develop vector vaccine candidates against both agents, and showed promising results. Recombinant MeV vectors encoding the unmodified SARS-CoV Spike protein induced high titers of neutralizing antibodies as well as IFN- T cell responses (5,6) and conferred protection to immunized animals upon pathogen challenge by lowering virus titers more than 100-fold (5). For MERS, we have demonstrated that high titers of neutralizing antibodies as well as effective and polyfunctional T cell responses were induced in vaccinated animals (7,8) and conferred protection (7). Based on these data, an MeV-based MERS vaccine candidate has been selected by the Coalition for Epidemic Preparedness Initiative for further clinical development (http:\/\/www.cepi.net\/research_dev\/our-portfolio). Here, we explored the potential of recombinant MeV as vectors for the expression of the SARS-CoV-2 spike protein (S) as successfully applied for the development of MERS (7,8) and SARS (5,6) vaccine candidates, as well as numerous other pathogens (4). The S glycoprotein was chosen as antigen for its role as primary target of neutralizing antibodies (6,7) and the exemplary capability of MERS-CoV S protein to trigger strong cell-mediated immune responses when expressed by MeV in our front-runner MERS vaccine candidate (7,8). The SARS-CoV-2 S protein-encoding gene was inserted into two different positions of the MeV genome to modulate antigen expression, and both.<\/p>\n","protected":false},"excerpt":{"rendered":"

\ufeffMoreover, the candidate still induces immunity against the measles, recognized as a looming second menace, when countries are forced to stop routine vaccination campaigns in the face of COVID-19. Abstract == The COVID-19 pandemic is caused by severe … <\/p>\n

Continue reading “\ufeffMoreover, the candidate still induces immunity against the measles, recognized as a looming second menace, when countries are forced to stop routine vaccination campaigns in the face of COVID-19”<\/span><\/a><\/div>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[49],"tags":[],"class_list":["post-1028","post","type-post","status-publish","format-standard","hentry","category-7-tm-receptors"],"_links":{"self":[{"href":"https:\/\/littleheroesfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/1028","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/littleheroesfoundation.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/littleheroesfoundation.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/littleheroesfoundation.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/littleheroesfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1028"}],"version-history":[{"count":1,"href":"https:\/\/littleheroesfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/1028\/revisions"}],"predecessor-version":[{"id":1029,"href":"https:\/\/littleheroesfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/1028\/revisions\/1029"}],"wp:attachment":[{"href":"https:\/\/littleheroesfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1028"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/littleheroesfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1028"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/littleheroesfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1028"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}